Everolimus

Name: Everolimus
SKU: J60139.MA

A rapamycin analog | CAS: 159351-69-6 | C53H83NO14 | 958.24 g/mol

更改视图

数量:

5 mg

10 mg

25 mg

试用 chem dex^TM 网络应用程序

货号 J60139.MA

又称 J60139-MA

价格（CNY)

数量:

10 mg

请求批量或定制报价

化学标识符

CAS159351-69-6

IUPAC Name(1R,9S,12S,15R,16Z,18R,19R,21R,23S,24E,26Z,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

Molecular FormulaC53H83NO14

InChI KeyHKVAMNSJSFKALM-CNPAPGRKSA-N

SMILESCO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)C=C(C)/[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=C/C=C(C)/[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO

查看更多内容

规格

规格表

FormPowder or crystals or crystalline powder or granules or amorphous solid

Appearance (Color)White to off-white to pale yellow

Assay from Suppliers CofA≥95.0%

Everolimus is a rapamycin analog. It is used to treat certain types of kidney cancer, breast cancer and brain tumor. It prevents transplant rejection by decreasing the activity of the immune system. It also act as a kinase inhibitor. It is used in the treatment of subependymal giant cell astrocytoma (SEGA; a type of brain tumor) in adults and children 1 year of age and older who have TSC.

This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

Solubility
Soluble in dimethysulfoxide,ethanol and chloroform. Slightly soluble in water.

Notes
Incompatible with strong oxidizing agents.

RUO – Research Use Only

General References:

Puricel, S.; Arroyo, D.; Corpataux N.; Baeriswyl, G.; Lehmann, N.; Kallinikou, Z.; Muller, O.; Allard, L.; Stauffer, J.; Togni, M.; Goy, J.; Cook, S. Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds. J. Am. Coll. Cardiol. 2015, 65 (8), 791-801.
Naruse, T.; Yanamoto, S.; Yamada, S.; Rokutanda, S.; Kawakita, A.; Kawasaki, G.; Umeda, M. Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma. Pathol. Oncol. Res. 2015, 21 (3), 765-773.